SLC5A2 and diabetes mellitus: SGLT2 inhibitors were shown to significantly improve diastolic function in the human heart, as confirmed in the myocardium of mice with or without DM and further in HFpEF models (Habibi et al., 2017; Pabel et al., 2018; Zhang et al., 2019).